Option Care Health (NASDAQ:OPCH) Price Target Raised to $38.00 at Barrington Research

Option Care Health (NASDAQ:OPCH) had its target price raised by Barrington Research from $33.00 to $38.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts have also recently commented on OPCH. UBS Group began coverage on Option Care Health in a report on Thursday, December 5th. They set a “neutral” rating and a $26.00 target price on the stock. Jefferies Financial Group raised Option Care Health from a “hold” rating to a “buy” rating and upped their price target for the company from $26.00 to $35.00 in a report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price target (down previously from $31.00) on shares of Option Care Health in a report on Friday, January 10th. Bank of America raised Option Care Health from a “neutral” rating to a “buy” rating and upped their price target for the company from $26.00 to $33.00 in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. upped their price target on Option Care Health from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.88.

Option Care Health Price Performance

Shares of NASDAQ:OPCH opened at $33.50 on Thursday. Option Care Health has a 12 month low of $21.39 and a 12 month high of $34.17. The stock has a market cap of $5.70 billion, a price-to-earnings ratio of 28.15, a PEG ratio of 2.30 and a beta of 1.35. The stock’s 50 day moving average price is $28.70 and its 200 day moving average price is $28.08. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32.

Hedge Funds Weigh In On Option Care Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in OPCH. Creative Planning grew its position in Option Care Health by 116.7% during the 3rd quarter. Creative Planning now owns 38,149 shares of the company’s stock worth $1,194,000 after purchasing an additional 20,546 shares in the last quarter. Raymond James & Associates grew its position in Option Care Health by 6.3% during the 3rd quarter. Raymond James & Associates now owns 85,279 shares of the company’s stock worth $2,669,000 after purchasing an additional 5,049 shares in the last quarter. International Assets Investment Management LLC grew its position in Option Care Health by 3,029.7% during the 3rd quarter. International Assets Investment Management LLC now owns 2,848 shares of the company’s stock worth $91,000 after purchasing an additional 2,757 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new position in Option Care Health during the 3rd quarter worth approximately $206,000. Finally, State of Alaska Department of Revenue grew its holdings in shares of Option Care Health by 3.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 19,871 shares of the company’s stock valued at $621,000 after acquiring an additional 735 shares in the last quarter. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.